Who Paid My Doc
John Mariani
Addiction Medicine New York, NY Medical Doctor
NPI 1245383405 CMS profile 541024
51 E 25Th St Ste 7E, New York, NY 10010
General payments
$38,062
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, John Mariani of New York, NY is reported in the CMS Open Payments database as having received $38,062 across 12 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 96th percentile of Addiction Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $2,750 | 1 | |
| 2022 | General | $7,150 | 1 | |
| 2021 | General | $12,100 | 2 | |
| 2020 | General | $16,062 | 8 |
Beside peers
- John Mariani
- Addiction Medicine median
- Middle half of Addiction Medicine
- National median
In program year 2025, general payments to John Mariani were reported at $0. Among 146 Addiction Medicine profiles paid that year, the median was $140 and the middle half received between $52 and $540.
Show as a table
| Year | John Mariani | Addiction Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $120 | $36–$323 | $163 |
| 2020 | $16,062 | $87 | $33–$262 | $114 |
| 2021 | $12,100 | $94 | $31–$394 | $132 |
| 2022 | $7,150 | $125 | $45–$667 | $149 |
| 2023 | $2,750 | $143 | $44–$445 | $160 |
| 2024 | $0 | $122 | $40–$490 | $164 |
| 2025 | $0 | $140 | $52–$540 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
161
Drug cost
$4,999
Branded share of claims
38.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl | Brand | 18 | $2,766 | |
| Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine | Brand | 12 | $747 | |
| Bupropion Xl Bupropion Hcl | Brand | 15 | $370 | |
| Buprenorphine Hcl | Generic | 13 | $286 | |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | Brand | 17 | $276 | |
| Lorazepam | Generic | 16 | $261 | |
| Fluoxetine Hcl | Generic | 23 | $175 | |
| Zolpidem Tartrate | Generic | 17 | $62 | |
| Sertraline Hcl | Generic | 18 | $32 | |
| Clonazepam | Generic | 12 | $25 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.
Records
12 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Addiction Medicine in New York
Related records
Addiction Medicine in New York
Practitioners in the same specialty and state, ranked by reported value.
All Addiction Medicine
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.